+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 22Years +
All Genders
ID07545980

Study of CelluJuve Injections for Moderate to Severe Nasolabial Fold Wrinkles with 24-Month Follow-Up

Led by Spiderwort Biotechnologies Inc. · Updated on 2026-05-22

12

Participants Needed

1

Research Sites

93 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the safety and effectiveness of CelluJuve4 for treating moderate to severe nasolabial fold wrinkles, commonly known as smile lines. The study is an open-label, single-center proof-of-concept trial. It includes adults aged 22 years or older with moderate to severe bilateral nasolabial folds assessed by the Wrinkle Severity Rating Scale. All participants will receive injections of CelluJuve4 into both nasolabial folds at the baseline visit. If necessary, a touch-up treatment will be given at Week 4. After the last treatment, participants will be followed for 24 months with visits every three months to monitor safety and effectiveness. The study includes photography of the treated area, blood tests for safety and immune response, and ultrasound imaging at selected visits. During each visit, researchers will check for common injection site reactions such as redness, pain, swelling, lumps, bruising, itching, and discoloration. Safety will be monitored through adverse event reports and laboratory testing. The main outcome measured is the change in wrinkle severity over two years, using the Wrinkle Severity Rating Scale. Participants are expected to attend all scheduled visits and follow study instructions throughout the study period.

CONDITIONS

Brief Title

CelluJuve® for the Treatment of Moderate to Severe NLFs

Research Team

S

Serpil Kucuktepe, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here